Amgen Ventures
Thousand Oaks, California, United StatesFounded 2004
Amgen Ventures is the corporate venture capital arm of Amgen, a global biotechnology company. It invests in emerging biotechnology companies to advance promising new medicines and technologies across oncology, inflammation, cardiovascular, neuroscience, and metabolic disorders.
38% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Average disclosed round size is $80.1M (across 71 rounds with reported amounts).
Portfolio
63
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Team
JN
Janis Naeve
Managing Director
GN
Gladys Nunez
Executive Director Amgen Ventures
MT
Miao-Chih Tsai
Business Development Manager
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
79 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CCartography | Series B | $67M | Oct 2025 |
 Mindset Medical | Series A | — | Jun 2024 |
 Vigil Neuroscience | Series A | $50M | Jan 2024 |
| BBioAge | Series D | $300M | Jan 2024 |
| TTiledb Inc | Series B | $34M | Oct 2023 |
 Generate Biomedicines | Series C | $273M | Sep 2023 |
| QQualis Corporation | Series B | $88M | Mar 2023 |
 TileDB | Series B | $34M | Jan 2023 |
 Seismic Therapeutic | Series B | $121M | Jan 2023 |
 Celsius Therapeutics | Series A | $63M | Mar 2022 |
| Celsius Therapeutics | Series B | $83M | Mar 2022 |
 BigHat Biosciences | Series B | $75M | Jan 2022 |
 Casma Therapeutics, Inc. | Series C | $46M | Jan 2022 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
 Akili Interactive Labs, Inc. | Series D | $110M | May 2021 |
| AAkili, Inc. | Series D | $110.0M | May 2021 |
 Hummingbird Bioscience | Series C | $125M | May 2021 |
| Vigil Neuroscience | Series B | — | Jan 2021 |
| AAkili, Inc. | Series D | $110M | Jan 2021 |
 SomaLogic | Series A | $214M | Dec 2020 |
 Science 37 | Series B | $40M | Aug 2020 |
 Enclear Therapies | Series A | $10M | Feb 2020 |
 Nkarta | Series B | $114M | Sep 2019 |
| GGNS Healthcare | Series D | $23M | Jul 2019 |
| RRheostat Therapeutics | Series A | $23M | Nov 2018 |
Page 1 of 4
Top Co-Investors
Alexandria Venture Investments12 shared
New Enterprise Associates9 shared
Samsara BioCapital9 shared
Atlas Venture8 shared
Mirae Asset8 shared
Celgene8 shared
Sanofi Ventures7 shared
Polaris Partners7 shared
Pfizer Ventures7 shared
Frazier Healthcare Partners7 shared
Alta Partners7 shared
Astellas Venture Management7 shared
Surveyor Capital6 shared
MPM Capital6 shared
Roche Venture Fund6 shared
T. Rowe Price5 shared
Dementia Discovery Fund4 shared
Logos Capital4 shared
RA Capital Management4 shared
ARCH Venture Partners4 shared
Last updated: 8 September 2026